Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo

Thrombosis Research

Volumn 128, Issue 1, 2011, Pages 68-76

  Van De Craen, Britt ^a   Scroyen, Ilse ^b   Abdelnabi, Rana ^a   Brouwers, Els ^a   Lijnen, H Roger ^b   Declerck, Paul J ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Fibrinolysis; Inhibition; Monoclonal antibodies; Mouse PAI 1

Indexed keywords

ALTEPLASE; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 33H1F7; MONOCLONAL ANTIBODY MP10F9; MONOCLONAL ANTIBODY MP11A11; MONOCLONAL ANTIBODY MP11C2; MONOCLONAL ANTIBODY MP12F10; MONOCLONAL ANTIBODY MP13G10; MONOCLONAL ANTIBODY MP13H7; MONOCLONAL ANTIBODY MP16E5; MONOCLONAL ANTIBODY MP18E10; MONOCLONAL ANTIBODY MP1H12; MONOCLONAL ANTIBODY MP21B5; MONOCLONAL ANTIBODY MP21F3; MONOCLONAL ANTIBODY MP21F7; MONOCLONAL ANTIBODY MP22E2; MONOCLONAL ANTIBODY MP25H3; MONOCLONAL ANTIBODY MP26H2; MONOCLONAL ANTIBODY MP2D2; MONOCLONAL ANTIBODY MP2D9; MONOCLONAL ANTIBODY MP2H2; MONOCLONAL ANTIBODY MP6H6; MONOCLONAL ANTIBODY MP8B1; MONOCLONAL ANTIBODY MP8H11; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT THROMBOPLASTIN; UNCLASSIFIED DRUG; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CROSS REACTION; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; FIBRINOLYSIS; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOEMBOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MODELS, ANIMAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOEMBOLISM; VITRONECTIN;

EID: 79958060613     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.01.011     Document Type: Article

References (49)

1. McMahon B, Kwaan HC. The Plasminogen Activator System and Cancer. Pathophysiol Haemost Thromb 2007;36(3-4):184-94.
2. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003;9(19):1545-64. (Pubitemid 36763492)
3. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005;93:631-40. (Pubitemid 40485397)
4. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009;7(1):4-13.
5. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005;3(1):35-45. (Pubitemid 41647113)
6. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, Vanzonneveld AJ, et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J 1986;5(10):2539-44.
7. Gils A, Declerck PJ. Structure-function relationships in serpins: Current concepts and controversies. Thromb Haemost 1998;80(4):531-41. (Pubitemid 28479333)
8. Kruithof EKO. Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects. Fibrinolysis 1988;2(Supp 2):59-70.
9. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985;260(21):1581-7.
10. Declerck PJ, Demol M, Alessi MC, Baudner S, Paques EP, Preissner KT, et al. Purification and characterization of a plasminogen activator inhibitor-1 binding protein from human plasma-Identification as a multimeric form of S-protein (vitronectin). J Biol Chem 1988;263(30):15454-61.
11. Declerck PJ, Demol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992;267(17):11693-6.
12. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990;346(6279):74-6.
13. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Vannuffelen A, Prendergast G, et al. Plasminogen activator inhibitor-1 gene deficient mice. I. Generation by homologeous recombination and characterization. J Clin Invest 1993;92(6):2746-55.
14. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Vandenoord JJ, Demol M, et al. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993;92(6):2756-60. (Pubitemid 24006541)
15. Westrick RJ, Eitzman DT. Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets 2007;8:996-1002. (Pubitemid 47578147)
16. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005;3(8):1879-83. (Pubitemid 41716575)
17. Juhan-Vague I, Valadier J, Alessi M, Aillaud M, Ansaldi J, Philip Joet C, et al. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987;57:67-72. (Pubitemid 17159602)
18. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, et al. Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis. Thromb Haemost 2004;91(3):438-49. (Pubitemid 38396865)
19. Debrock S, Declerck PJ. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms. Biochim Biophys Acta Protein Struct Mol Enzymol 1997;1337(2):257-66. (Pubitemid 27073496)
20. Nielsen LS, Andreasen PA, Grondahlhansen J, Huang JY, Kristensen P, Dano K. Monoclonal antibodies to human 54, 000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells-inhibitor neutralization and one-step affinity purification. Thromb Haemost 1986;55(2):206-12. (Pubitemid 16013687)
21. Keijer J, Linders M, Vanzonneveld AJ, Ehrlich HJ, Deboer JP, Pannekoek H. The interaction of plasminogen activator inhibitor-1 with plasminogen activators (tissue-type and urokinase-type) and fibrin - Localization of interaction sites and physiological relevance. Blood 1991;78(2):401-9.
22. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhanvague I, Collen D. Measurement of plasminogen activator inhibitor-1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988 Jan;71(1):220-5. (Pubitemid 18050415)
23. Gils A, Pedersen KE, Skottrup P, Christensen A, Naessens D, Deinum J, et al. Biochemical importance of glycosylation of plasminogen activator inhibitor-I. Thromb Haemost 2003;90(2):206-17. (Pubitemid 37006281)
24. Dupont DM, Blouse GE, Hansen M, Mathiasen L, Kjelgaard S, Jensen JK, et al. Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem 2006;281(47):36071-81. (Pubitemid 46041340)
25. Berry CN, Lunven C, Lechaire I, Girardot C, O'Connor SE. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. Br J Pharmacol 1998;125(1):29-34. (Pubitemid 28418752)
26. Hansen M, Busse MN, Andreasen PA. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur J Biochem 2001;268(23):6274-83. (Pubitemid 33132049)
27. Sancho E, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994;224(1):125-34. (Pubitemid 24267113)
28. Bijnens AP, Gils A, Knockaert I, Stassen JM, Declerck PJ. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem 2000;275(9):6375-80. (Pubitemid 30129932)
29. Galfré G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Meth Enzymol 1981;73:3-46.
30. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003;23(6):1122-7. (Pubitemid 36713571)
31. Verheijen JH, Chang GTG, Kluft C. Evidence for the occurence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost 1984;51(3):392-5. (Pubitemid 14097900)
32. Verbeke K, Gils A, Declerck PJ. Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs. J Thromb Haemost 2004;2(2):298-305. (Pubitemid 40186045)
33. Scroyen I, Jacobs F, Cosemans L, De Geest B, Lijnen HR. Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo. Thromb Haemost 2009;101(2):388-93.
34. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, et al. Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. J Thromb Haemost 2005;3(12):2745-53. (Pubitemid 41819804)
35. Dewilde M, Van De Craen B, Compernolle G, Madsen JB, Strelkov S, Gils A, et al. Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences. J Struct Biol 2010;171:95-101.
36. Hillmayer K, Vancraenenbroeck R, De Maeyer M, Compernolle G, Declerck PJ, Gils A. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2008;6(11):1892-9.
37. Ngo TH, Verheyen S, Knockaert I, Declerck PJ. Monoclonal antibody-based immunoassays for the specific quantitation of rat PAI-1 antigen and activity in biological samples. Thromb Haemost 1998 Apr;79(4):808-12. (Pubitemid 28163859)
38. Declerck PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost 1995 Nov;74(5):1305-9.
39. Ngo TH, Hoylaerts MF, Knockaert I, Brouwers E, Declerck PJ. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric up-regulation of its antiadhesive properties. J Biol Chem 2001;276(28):26243-8.
40. Scroyen I, Christiaens V, Lijnen HR. No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation. J Thromb Haemost 2007 Jan;5(1):139-45. (Pubitemid 44921079)
41. Gils A, Meissenheimer LM, Compernolle G, Declerck PJ. Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 2009;102(3):609-10.
42. Cale JM, Li S-H, Warnock M, Su EJ, North PR, Sanders KL, et al. Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1. J Biol Chem 2010.
43. Helenius A, Aebi M. Intracellular functions of N-linked glycans. Science 2001;291(5512):2364-9. (Pubitemid 32231791)
44. Serrano R, Barrenetxe J, Orbe J, Rodriguez JA, Gallardo N, Martinez C, et al. Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats. Am J Physiol Regul Integr Comp Physiol 2009;297(5):R1563-9.
45. Brogren H, Sihlbom C, Wallmark K, Lonn M, Deinum J, Karlsson L, et al. Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin. Thromb Res 2008;122(2):271-81.
46. Egelund R, Einholm AP, Pedersen KE, Nielsen RW, Christensen A, Deinum J, et al. A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands - Ligand-induced serpin polymerization. J Biol Chem 2001;276(16):13077-86.
47. Rupin A, Gaertner R, Mennecier P, Richard I, Benoist A, De Nanteuil G, et al. S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thromb Res 2008;122(2):265-70.
48. Gorlatova NV, Tale JM, Elokdah H, Li DH, Fan's K, Warnock M, et al. Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitory. J Biol Chem 2007;282(12):9288-96. (Pubitemid 47093491)
49. Jensen JK, Durand MKV, Skeldal S, Dupont DM, Bodker JS, Wind T, et al. Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal. FEBS Lett 2004;556(1-3):175-9. (Pubitemid 38058575)